Atara Biotherapeutics (NASDAQ:ATRA) Lowered to “Hold” Rating by RODMAN&RENSHAW

RODMAN&RENSHAW lowered shares of Atara Biotherapeutics (NASDAQ:ATRA) from a strong-buy rating to a hold rating in a report published on Tuesday morning,Zacks.com reports.

Other research analysts have also issued reports about the stock. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday. Rodman & Renshaw started coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, Canaccord Genuity Group decreased their target price on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Atara Biotherapeutics Stock Up 13.9 %

Shares of NASDAQ:ATRA opened at $6.89 on Tuesday. Atara Biotherapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $39.50. The firm’s 50-day simple moving average is $12.16 and its 200-day simple moving average is $9.97. The company has a market cap of $39.69 million, a price-to-earnings ratio of -0.27 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the prior year, the firm posted ($16.50) EPS. On average, research analysts forecast that Atara Biotherapeutics will post -9.86 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of large investors have recently bought and sold shares of ATRA. Geode Capital Management LLC raised its holdings in shares of Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 4,043 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics in the 2nd quarter valued at about $53,000. FMR LLC lifted its holdings in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. State Street Corp lifted its holdings in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth about $79,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.